Cannabinoids Impact on Cognition: A Review from the Neurobiological Perspective

Document Type : Review Article


1 School of medicine, Iran university of medical science, Tehran, Iran

2 Medical Laboratory Sciences Department, College of Health Sciences, University of Human Development, Sulaymaniyah, Iraq

3 Department of Medicine, Iran university of medical science, Tehran, Iran

4 Department of Chemistry, University of Zanjan, Zanjan, Iran


Cannabis is a widely used psychoactive substance in society, especially among the youngest. The use of this substance has been consistently associated with various health problems, many of which have in common an alteration in the cognitive manifestations of behavior, including memory, attention, emotion and decision-making. Evidence was found that cannabinoids, the active substance in Cannabis, negatively impact short-term memory, working memory, and decision-making. Likewise, cannabinoids affect attention and the interaction between cognitive events and emotion. This information can be used as a biological plausibility argument to interpret a series of clinical and epidemiological findings in which the use of Cannabis has been shown to be related to problems such as traffic accidents, psychosis, depression, poor academic performance, among others.


Main Subjects

  1. United Nations Office for Drug Control and Crime Prevention. World drug report 2011. Vienna: UNODC; 2011.
  2. Degenhardt L, Chiu WT, Sampson N, Kessler RC, Anthony JC, Angermeyer M, et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med. 2008;5(7):e141.
  3. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698):1383-91.
  4. Gerberich SG, Sidney S, Braun BL, Tekawa IS, Tolan KK, Quesenberry CP. Cannabis use and injury events resulting in hospitalization. Ann Epidemiol. 2003;13(4):230-7.
  5. Mura P, Kintz P, Ludes B, Gaulier JM, Marquet P, MartinDupont S, et al. Comparison of the prevalence of alcohol, cannabis and other drugs between 900 injured drivers and 900 control subjects: results of a french collaborative study.
  6. forensic Sci Int. 2003;133(1-2):79-85.
  7. Ramaekers JG, Berghaus G, van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend. 2004;73(2):109-19.
  8. Laumon B, Gadegbeku B, Martin JL, Biecheler MB. Cannabis intoxication and fatal road crashes in france: population based case-control study. BMJ. 2005;331(7529):1371.
  9. Grotenhermen f, Leson G, Berghaus G, Drummer OH, Kruger HP, Longo M, et al. Developing limits for driving under cannabis. Addiction. 2007;102(12):1910-7.
  10. fiestas f, Radovanovic M, Martins SS, Medina-Mora ME, Posada-Villa J, Anthony JC. Cross-national differences in clinically significant cannabis problems: epidemiologic evidence from ‘cannabis-only’ smokers in the United States, Mexico, and Colombia. BMC Public Health. 2010;10:152.
  11. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319-28.
  12. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend. 2003;71(1):37-48.
  13. Degenhardt L. The link between cannabis use and psychosis:
  14. furthering the debate [editorial]. Psychol Med. 2003;33(1):3-6.
  15. de Graaf R, Radovanovic M, van Laar M, fairman B, Degenhardt L, Aguilar-Gaxiola S, et al. Early cannabis use and estimated risk of later onset of depression spells: Epidemiologic evidence from the population-based World Health Organization World Mental Health Survey Initiative. Am J Epidemiol. 2010;172(2):149-59.
  16. Lee S, Tsang A, Breslau J, Aguilar-Gaxiola S, Angermeyer M, Borges G, et al. Mental disorders and termination of education in high-income and low- and middle-income countries:
  17. epidemiological study. Br J Psychiatry. 2009;194(5):411-7.
  18. Breslau J, Miller E, Joanie Chung WJ, Schweitzer JB. Childhood and adolescent onset psychiatric disorders, substance use, and failure to graduate high school on time. J Psychiatr Res. 2011;45(3):295-301.
  19. Breslau J, Lane M, Sampson N, Kessler RC. Mental disorders and subsequent educational attainment in a US national sample. J Psychiatr Res. 2008;42(9):708-16.
  20. Borges G, Mora-Icaza ME, Benjet C, Lee S, Lane M, Breslau J. Influence of mental disorders on school dropout in Mexico. Rev Panam Salud Publica. 2011;30(5):477-83.
  21. fergusson DM, Horwood LJ, Beautrais AL. Cannabis and educational achievement. Addiction. 2003;98(12):1681-92.
  22. fergusson DM, Boden JM. Cannabis use and later life outcomes. Addiction. 2008;103(6):969-76; discussion 77-8.
  23. Mesulam MM. from sensation to cognition. Brain. 1998;121 (Pt 6):1013-52.
  24. fernandez-Serrano MJ, Perez-Garcia M, Verdejo-Garcia A. What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance? Neurosci Biobehav Rev. 2011;35(3):377-406.
  25. Ranganathan M, D’Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl). 2006;188(4):425-44.
  26. fried PA, Watkinson B, Gray R. Neurocognitive consequences of marihuana--a comparison with pre-drug performance. Neurotoxicol Teratol. 2005;27(2):231-9.
  27. Jager G, Van Hell HH, De Win MM, Kahn RS, Van Den Brink W, Van Ree JM, et al. Effects of frequent cannabis use on hippocampal activity during an associative memory task. Eur Neuropsychopharmacol. 2007;17(4):289-97.
  28. Kelleher LM, Stough C, Sergejew AA, Rolfe T. The effects of cannabis on information-processing speed. Addict Behav. 2004;29(6):1213-9.
  29. Pattij T, Wiskerke J, Schoffelmeer AN. Cannabinoid modulation of executive functions. Eur J Pharmacol. 2008;585(2-3):458-63.
  30. Block RI, Ghoneim MM. Effects of chronic Cannabis use on human cognition. Psychopharmacology (Berl). 1993;110(12):219-28.
  31. Miller EK, Cohen JD. An integrative theory of prefrontal cortex function. Annu Rev Neurosci. 2001;24:167-202.
  32. Pope HG, Jr., yurgelun-Todd D. The residual cognitive effects of heavy Cannabis use in college students. JAMA. 1996;275(7):521-7.
  33. fletcher JM, Page JB, francis DJ, Copeland K, Naus MJ, Davis CM, et al. Cognitive correlates of long-term cannabis use in Costa Rican men. Arch Gen Psychiatry. 1996;53(11):1051-7.
  34. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA. 2002;287(9):1123-31.
  35. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Doserelated neurocognitive effects of Cannabis use. Neurology. 2002;59(9):1337-43.
  36. Kanayama G, Rogowska J, Pope HG, Gruber SA, yurgelunTodd DA. Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology (Berl). 2004;176(3-4):239-47.
  37. freedman            Schizophrenia.      N             Engl        J              Med.
  38. 2003;349(18):1738-49.
  39. O’Shea M, Singh ME, McGregor IS, Mallet PE. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol. 2004;18(4):502-8.
  40. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296(5568):678-82.
  41. Rodriguez de fonseca f, Del Arco I, Bermudez-Silva fJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 2005;40(1):2-14.
  42. Llano I, Leresche N, Marty A. Calcium entry increases the sensitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory synaptic currents. Neuron.
  43. 1991;6(4):565-74.
  44. Pitler TA, Alger BE. Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells. J Neurosci. 1992;12(10):4122-32.
  45. Wilson RI, Kunos G, Nicoll RA. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron. 2001;31(3):453-62.
  46. Diana MA, Marty A. Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol. 2004;142(1):9-19.
  47. Egerton A, Allison C, Brett RR, Pratt JA. Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev. 2006;30(5):680-95.
  48. Riedel G, Davies SN. Cannabinoid function in learning, memory and plasticity. Handb Exp Pharmacol. 2005(168):445-77.
  49. Phelps EA. Emotion and cognition: insights from studies of the human amygdala. Annu Rev Psychol. 2006;57:27-53.
  50. Ochsner KN, Phelps E. Emerging perspectives on emotioncognition interactions. Trends Cogn Sci. 2007;11(8):317-8.
  51. Barsalou LW. Grounded cognition. Annu Rev Psychol. 2008;59:617-45.
  52. Pope HG, Jr., Gruber AJ, yurgelun-Todd D. Residual neuropsychologic effects of cannabis. Curr Psychiatry Rep. 2001;3(6):507-12.
  53. Pope HG, Jr., Gruber AJ, Hudson JI, Huestis MA, yurgelunTodd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. 2001;58(10):909-15.
  54. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen f, Pelz S, Becker S, Kunert HJ, et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry. 2000;68(6):719-25.
  55. Sanchis-Segura C, Cline BH, Marsicano G, Lutz B, Spanagel R. Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology (Berl). 2004;176(2):223-32.
  56. Lynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: a review. Addiction. 2000;95(11):1621-30.
  57. fridberg DJ, Queller S, Ahn Wy, Kim W, Bishara AJ, Busemeyer JR, et al. Cognitive Mechanisms Underlying Risky Decision-Making in Chronic Cannabis Users. J Math Psychol. 2010; 54(1):28-38.
  58. Lane SD, Cherek DR, Tcheremissine OV, Lieving LM, Pietras CJ. Acute Cannabis effects on human risk taking. Neuropsychopharmacology. 2005;30(4):800-9.
  59. Lane SD, yechiam E, Busemeyer JR. Application of a computational decision model to examine acute drug effects on human risk taking. Exp Clin Psychopharmacol. 2006;14(2):254-64.
  60. fuster JM. frontal lobe and cognitive development. J Neurocytol. 2002;31(3-5):373-85.
  61. Ellgren M, Artmann A, Tkalych O, Gupta A, Hansen HS, Hansen SH, et al. Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol. 2008;18(11):826-34.
  62. Churchwell JC, Lopez-Larson M, yurgelun-Todd DA. Altered frontal cortical volume and decision making in adolescent cannabis users. front Psychol. 2010;1:225.
  63. Siadati SA, Afzali M, Sayyadi, M. Could silver nano-particles control the 2019-nCoV virus?; An urgent glance to the past. Chemical Review and Letters 2020; 3(1): 9-11.
  64. Siadati SA, Rezvanfar MA, Babanezhad E, Beheshti A, Payab M. Harmony of operations of some vitamins in controlling the 2019-nCoV virus based on scientific reports. Chemical Review and Letters 2020; 3(4): 202-206.